Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2004 Apr;57(4):525-8.
doi: 10.1111/j.1365-2125.2003.02044.x.

Professional athletes suffering from familial hypercholesterolaemia rarely tolerate statin treatment because of muscular problems

Affiliations

Professional athletes suffering from familial hypercholesterolaemia rarely tolerate statin treatment because of muscular problems

H Sinzinger et al. Br J Clin Pharmacol. 2004 Apr.

Abstract

Aims: Muscular problems are the major group of side-effects during statin treatment. They are known to occur much more frequently during and after exercise.

Methods and results: For the last 8 years we have monitored 22 professional athletes in whom, because of familial hypercholesterolaemia, treatment with different statins was attempted. Only six out of the 22 finally tolerated at least one member of this family of drugs. In three of these six the first statin prescribed allowed training performance without any limitation. Changing the drug demonstrated that only two tolerated all the four or five statins examined (atorvastatin, fluvastatin, lovastatin, pravastatin, simvastatin). Cerivastatin was not among the statins prescribed.

Conclusions: These findings indicate that in top sports performers only about 20% tolerate statin treatment without side-effects. Clinical decision making as to lipid lowering therapy thus becomes a critical issue in this small subgroup of patients.

PubMed Disclaimer

References

    1. Gotto AM, Grundy SM. Lowering LDL-cholesterol: questions from recent analysis of clinical trials. Data from the Interdisciplinary Council of Reducing the Risk for Coronary Heart Disease. Circulation. 1999;99:E1–E7. - PubMed
    1. Phillips PS, Haas RH, Bannykh S, Hathaway S, Gray NL, Kimura BJ, England JDF. Statin-associated myopathy with normal creatine kinase levels. Ann Int Med. 2002;137:581–5. - PubMed
    1. Heart Protection Study Collaborative Group. MRC/BHF Heart protection study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomized placebo-controlled trial. Lancet. 2002;360:7–22. - PMC - PubMed
    1. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Lancet. 1994;344:1383–9. - PubMed
    1. Witztum JL. Drugs used in the treatment of hyperlipoproteinemia. In: Harrison JG, et al., editors. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 9. New York: McGraw-Hill; 1996.

Substances